Develops next-generation CAR T cell therapies for hematologic cancers, glioblastoma, and rare genetic diseases by in-licensing, manufacturing, and advancing clinical-stage treatments. The company addresses the limitations of current therapies by providing scalable, uniform manufacturing processes that ensure consistent product quality and efficacy.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases often suffer from limitations in manufacturing scalability and consistency, which can impact product quality and efficacy. This can hinder the broad application and affordability of these potentially curative treatments.
Solution
Mustang Bio is a biopharmaceutical company focused on developing and manufacturing next-generation cell and gene therapies to address the unmet needs in treating hematologic cancers, glioblastoma, and rare genetic diseases. The company in-licenses and advances clinical-stage treatments, leveraging partnerships with leading medical institutions to develop CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID). Mustang Bio aims to overcome the challenges of current therapies by establishing scalable and uniform manufacturing processes that ensure consistent product quality, efficacy, and accessibility for a wider range of patients.
Target Audience
The primary target audience includes patients with hematologic cancers, glioblastoma, and rare genetic diseases, as well as the physicians and medical institutions that treat these conditions.
Features
- Development of CAR T cell therapies targeting hematologic cancers and solid tumors
- CRISPR/Cas9-enhanced CAR T therapies for improved precision and efficacy
- Lentiviral gene therapy programs for rare genetic diseases like XSCID
- Focus on scalable and uniform manufacturing processes to ensure consistent product quality
- Partnerships with top medical institutions to advance clinical-stage treatments
- Clinical trials evaluating the safety and efficacy of novel cell and gene therapies
- Proprietary manufacturing platform designed to overcome limitations of current CAR T therapies